76541-78-1

Upstream product

• 76541-76-9 tetraethyl 4-phenylbutylidene 1,1-diphosphonate 
• 637-59-2 1-Bromo-3-phenylpropane 

Downstream Products

• 76541-81-6 tetramethyl (4-phenylbutylidene)bis(phosphonate) 

Relevant academic research and scientific papers

BIS-H-PHOSPHINIC ACID DERIVATIVES AS PRECURSORS TO THERAPEUTIC BISPHOSPHONATES AND USES THEREOF

A novel class of compounds, i.e., 1,1-bis-H-phosphinates (or 1,1-bis-H-phosphinic acid derivatives) are provided. Also provided are novel methods for producing 1,1-bis-H-phosphinates and 1,1-bis-H-phosphinate conjugates. These compounds and conjugates are used as precursors of bisphosphonates and bisphosphonate conjugates, respectively, or as prodrugs directly for treating bone-related and various other diseases.

Method of inhibiting squalene synthetase

There is provided a squalene inhibitory composition containing a 1,1-bisphosphonic acid compound, a lower alkyl ester thereof, or a salt thereof, which is useful for treating hypercholesterolemia. There are also provided novel compounds having squalene sy

gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity

New diphosphonate compounds and related derivatives were synthesized and investigated for their activity in specifically inducing plasma high density lipoproteins (HDL) and high density lipoprotein cholesterol (HDL-C) in normal rats. The screening of nume

Anti-atherosclerotic pharmaceutical compositions containing diphosphonate compounds

The present invention relates to a pharmaceutical composition for increasing the relative quantity of circulating high density lipoproteins favorable augmentating the alpha/beta lipoprotein cholesterol ratios and clearing cholesterol and lipids from certain tissues and inducing hypotensive activity comprising administering to a human an effective amount of a compound of the formula: STR1 where X is H, OH, or STR2 R and R' identical or different are H, CH3 or C2 H5 ; m is zero or 1; and A is selected from the group comprising (CH3)3 C--, Y--C6 H4 --, Y--C6 H4 --O--C(CH3)2 --, Y--C6 H4 --C(CH3)2 --, Y--C6 H4 --C(O)--C6 H4 --, Y--C6 H4 --(CH2)n -- and Y--C6 H4 --O--(CH2)n --, where n is an integer from 1 to 6 and Y is H, CH3, OCH3, a halogen, and a pharmaceutically acceptable excipient.